A trend analysis is a method of analysis that allows traders to predict what will happen with a stock in the future. The shares were sold at an average price of $44.76, for a total transaction of $1,611,360.00. Finally, BidaskClub cut Juno Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Tuesday, July 11th.
In related news, CEO Hans Edgar Bishop sold 270,250 shares of Juno Therapeutics stock in a transaction that occurred on Tuesday, January 16th.
The company reported its EPS on 9/29/2017. Three analysts have rated the stock with a sell rating, ten have issued a hold rating and seven have given a buy rating to the company. Wedbush downgraded shares of Juno Therapeutics from an "outperform" rating to a "neutral" rating in a research note on Wednesday. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company's stock valued at $102,000 after acquiring an additional 228 shares during the period. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Recently, investment analysts covering the stock have updated the mean rating to 1.33. The stock was sold at an average price of $54.95, for a total value of $366,296.70. The disclosure for this sale can be found here. Trading volume for Juno Therapeutics Inc. was 8.44 Million in its previous trading session. This gauge is crucial in determining whether investors are moved toward the direction of buying more of the stock, or else doing the contradictory side and selling more of the stock. Vanguard Group Inc. lifted its holdings in Juno Therapeutics by 2.1% in the 2nd quarter. BlackRock Inc. now owns 4,294,296 shares of the biopharmaceutical company's stock worth $128,357,000 after purchasing an additional 110,503 shares during the last quarter. Bronfman E.L. Rothschild L.P. grew its position in shares of Juno Therapeutics by 27,376.9% during the 3rd quarter. Earnings, with 13 analysts believing the company would generate an Average Estimate of $-1.01. State Street Corp raised its position in shares of Juno Therapeutics by 16.3% in the fourth quarter. Capital World Investors now owns 2,425,000 shares of the biopharmaceutical company's stock worth $72,483,000 after purchasing an additional 295,000 shares during the last quarter. Russell Investments Group Ltd. acquired a new position in shares of Juno Therapeutics during the fourth quarter worth $204,000. Raymond James Financial reiterated a "buy" rating on shares of Juno Therapeutics in a report on Wednesday. Juno Therapeutics earned a coverage optimism score of 0.15 on Accern's scale. The stock had a trading volume of 5,220,193 shares, compared to its average volume of 2,846,186. Juno Therapeutics has a twelve month low of $19.07 and a twelve month high of $74.35. The company has a current ratio of 4.77, a quick ratio of 4.77 and a debt-to-equity ratio of 0.01.
Juno Therapeutics (NASDAQ:JUNO) last issued its quarterly earnings data on Wednesday, November 1st.
Maximum and minimum EPS estimate for the current quarter is projected at $-0.67 and $-1.34, respectively, according to 8 analysts. The business had revenue of $44.80 million during the quarter, compared to analyst estimates of $18.12 million.
Juno Therapeutics Inc. (NASDAQ:JUNO) gross margin percentage stands at 0% while its operating margin for the past trailing twelve month is 0 percent and its overall profit margin (ttm) is 0 Percent. The firm's revenue was up 115.4% compared to the same quarter a year ago.
Juno Therapeutics, Inc. (NASDAQ:JUNO)'s earnings per share has been growing at a 0 percent rate over the past 5 year when average revenue increase was noted as 0 percent.
TRADEMARK VIOLATION WARNING: "Juno Therapeutics Target of Unusually High Options Trading (JUNO)" was first published by Registrar Journal and is the sole property of of Registrar Journal. BlackRock Inc. lifted its holdings in Juno Therapeutics by 2.6% in the 2nd quarter.